Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/717—Celluloses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/10—Laxatives

Definitions

• the present invention relates to an improved process for preparing compressed methylcellulose containing tablets which meet USP disintegration standards.
• cellulose ethers such as methylcellulose and carboxymethylcellulose suggests that these agents are effective as bulk laxatives. Their mechanism of action involves increasing both the water content of, and the bulk content of the stool, as well as lubricating the stool; thereby relieving constipation.
• Cellulose ethers have been administered as bulk laxatives in dosage forms comprising of tablets, suspensions, and bulk powders; the latter as sugar-free or in compositions containing high amounts of sugar.
• Cellulose ethers administered as suspensions in water may contain high concentrations of sucrose or other sugars and flavors.
• the sugar competes with the cellulose ether for available water, thereby preventing the cellulose ether from hydrating sufficiently to form a gel.
• the advantages of using a suspension formulation is that the cellulose ether is dispersed sufficiently to avoid any significant lumping in the digestive tract.
• these suspensions are viscous, semi-gelatinous, and visually unappealing to the consumer.
• Another disadvantage is the unpalatability of the suspensions due to the slimy mouth feel and extreme sweetness of such suspensions. Hence, these dosage forms have not gained significant consumer acceptance.
• Bulk powders of cellulose ethers often exhibit lumping of individual particles and gelation and thus, remain undissolved as they pass through the digestive tract. Additionally, administration of bulk powders has caused cramping, nausea, and vomiting in some patients. Therefore, bulk powders are not the preferred dosage form for cellulose ethers.
• Sugar encrusted cellulose ethers have been proposed as alternatives to the bulk powders containing high amounts of sugar. Such formulations have 1) less sugar such as natural sugar or combination of sugars such as sucrose, glucose, fructose or corn syrup solids; 2) lower caloric value; and 3) are readily dispersed in cold aqueous liquids.
• Citrucel® Orange Flavor a bulk forming laxative containing methylcellulose as its active ingredient, was first introduced into the market in 1986.
• This product contains 15 g of sucrose in a 19 g adult dose, which corresponds to a 2 g dose of methylcellulose.
• a natural flavored formula lower in caloric value and containing only 1 g sucrose, was developed and introduced in 1988. Additional patent protection for this product has focused on producing a sugar-free and virtually calorie-free powder.
• the product has a sugar-free sweetener, a dispersing agent, other excipients, and flavoring and was marketed in 1991 as Sugar Free Citrucel® Orange Flavor.
• the present invention relates to an improved process for preparing methylcellulose tablets which are readily dispersible and meet United States Pharmacopoeia standards for disintegration.
• the methylcellulose is compressed into tablets which contain an edible calcium salt, in preferred w/w ratios.
• the tablets rapidly disintegrate, in-vitro in 0.1 N hydrochloric acid and water at 37 ⁇ 0.5° C.
• tabletted cellulose ethers do not readily dissolve in the digestive tract because these cellulose ethers are highly hygroscopic.
• the outer portion of the tablet is said to form a gel-like hydrate that prevents the tablet from breaking up and greatly retards the hydration of the inner portion of the tablet.
• the present invention overcomes this art recognized problem and involves preparation of a novel composition, and process of making, by which a rapidly disintegrating tablet of methylcellulose is prepared.
• the tablets are prepared by a novel process involving a high-shear wet granulation method, followed by fluidized bed drying, milling, mixing with the other ingredients, and compression.
• the present invention is to a methylcellulose tablet which comprises methylcellulose having a viscosity of >1000 centipoise, and at least one excipient selected from an edible calcium salt. It is recognized that the formulation will also include diluents and fillers well known to the skilled artisan.
• the tablet formulations of the present invention are advantageous over other dosage forms of methylcellulose because of their convenience of administration and rapid disintegration. This is in contrast to tablets of methylcellulose, formulated as 100% w/w methylcellulose in a 0.5 gm caplet which have been found not to disintegrate in 0.1N HCl solution, using a conventional dissolution apparatus even after two hours.
• the present tablets should disintegrate in 0.1N HCl from about 20 to about 30 minutes, preferably from about 10 to about 19 minutes, and more preferably less than 10 minutes; and in water, the tablets should disintegrate from about 25 to about 30 minutes, preferably from about 15 to about 24 minutes, and more preferably less than 15 minutes.
• mw low molecular weight methylcellulose
• the fibers must have a sufficient viscosity to gel and retain water in the gut to provide the stool bulking and softening for laxation use.
• Methocel A4M made by Dow Chemical Company, Midland Michigan as Dow Methocel A4M, having a viscosity of about 3000 to about 5,600 cps, which is within 75 to 140% of the desired target viscosity herein.
• Some of the additional diluents or fillers for use in this formulation are preferably swellable agents, and may include, but are not limited to, various grades of microcrystalline cellulose, such as Avicel PH 101, Avicel PH 102, & Avicel PH 200; Corn starch; or Starch 1500.
• the edible calcium salts suitable for use herein include but are not limited to, dibasic calcium phosphate dihydrate, calcium phosphate anhydrous, and tribasic calcium phosphate; or mixtures thereof.
• a preferred edible calcium salt is the dibasic calcium phosphate dihydrate salt, which salt also provides good compressibility.
• microcrystalline cellulose is added, it is preferably from about 50 to 180 microns in size, more preferably about 50.
• Avicel PH 101 has a mean particle size of about 50; Avicel PH 102 has a mean particle size of about 100; and Avicel PH 200 has a mean particle size of about 190 microns.
• the preferred microcrystalline cellulose is Avicel PH 101.
• ratio of methylcellulose to edible calcium salt, and additional diluents will depend upon the diluent chosen, and is within the skill of the art to determine with preciseness the necessary ratios.
• Methylcellulose Dibasic calcium phosphate, dihydrate, from about 2 to about 4:1, preferably from about 2.6-3.1:1;
• Methylcellulose:Calcium phosphate anhydrous from about 2 to about 4:1, preferably from about 3.1:1
• Methylcellulose Tribasic calcium phosphate, WG® from about 2 to about 4:1, preferably from about 3.1:1
• Methylcellulose microcrystalline cellulose, from about 2:1 to about 14:1.
• Avicel PH 101 from about 2.2-13.5:1; for Avicel PH 102 from about 2.4-8.3:1; and for Avicel PH 200 from about 2.4-4:1.
• Methylcellulose Core starch from about 7.5 to about 15, preferably from about 13.5:1;
• Methylcellulose Starch 1500, from about 2.0 to about 5.0:1, preferably from about 2.4: 1;
• Methylcellulose:Explotab from about 5 to about 25:1, preferably from about 8.1 to about 21.3:1.
• the formulation may also include additional components such as, but are not limited to, a wetting agent, (super)disintegrant(s), a second binding agent(s), dye(s) or colouring agents, and lubricants, which are preferably used to prepare a tablet that is wetted readily, and is rapidly disintegrated in 0.1N hydrochloric acid and water, the USP test standard test for methylcellulose.
• additional components such as, but are not limited to, a wetting agent, (super)disintegrant(s), a second binding agent(s), dye(s) or colouring agents, and lubricants, which are preferably used to prepare a tablet that is wetted readily, and is rapidly disintegrated in 0.1N hydrochloric acid and water, the USP test standard test for methylcellulose.
• a preferred wetting agent is sodium lauryl sulfate.
• a preferred lubricant is magnesium stearate.
• a preferred binding agent is polyvinylpyrrolidone, or PVP, such as Povidone 29K/32.
• PVP polyvinylpyrrolidone
• the PVP is present in an amount of about 4 to about 6.5% w/w.
• a preferred disintegrating agent is sodium starch glycolate, such as Explotab®.
• the sodium starch glycolate is present in an amount of about 3 to about 8% w/w.
• Sodium lauryl sulfate Explotab: Calcium phosphate, anhydrous: Povidone 29K/32: Magnesium stearate include: 0.40:3.5:21.6:6.4:1.0
• Methylcellulose:Povidone preferably PVP 29K/32, from about 8 to about 22:1, preferably from about 10.4:1-16.7:1;
• Methylcellulose:Magnesium stearate from about 50 to about 150;1, preferably from about 58-132:1;
• lubricants to magnesium stearate include, but are not limited to, calcium stearate, sodium stearate, Cab-O-Sil, Syloid, stearic acid and talc.
• binding agents to PVP include but are not limited to, hydroxypropylcellulose, hydroxypropyl methylcellulose, acacia, gelatin, tragacanth, pregelatinized starch and starch.
• Explotab® alternatives include but are not limited to, sodium carboxymethylcellulose, Ac-di-sol®, carboxymethylcellulose, veegum, alginates, agar, guar, tragacanth, locust bean, karaya, pectin, and crospovidone.
• Alternative wetting agents to sodium lauryl sulfate include but are not limited to, magnesium lauryl sulfate.
• a sugar-free formulation has the advantage that it can be administered easily to consumers with blood sugar disorders or to diabetics in need of such preparations.
• the formulations contain calcium, such as dibasic calcium phosphate dihydrate. These formulations, for instance, will contain approximately an 80 mg/dose, anticipating formulating a 0.5 gm/tablet X 2 tablets/dose of methylcellulose. If desired the amount of calcium can be increased in these tablets to provide increased therapeutic value to the consumer.
• calcium such as dibasic calcium phosphate dihydrate.
• the tablets of this invention are advantageously administered in a single dose which may contain as much as 500 to 1000 mg of methyl cellulose tablet, or in a plurality of smaller doses containing as little as 250 mg per tablet. Most preferably, for laxative effect, each tablet will contain about 500 mg methylcellulose and the patient may take 1 to 2 tablets per dose. This dosage, of 1000 mg should adequately provide optimal laxative efficacy.
• a preferred range of methylcellulose per tablet is optimally from about 450 to 550 mg, preferably about 500 mg; or alternatively from about 200 to about 300 mg for a smaller tablet, preferably about 250 mg; or even in increments of about 125 mg tablet, i.e. 75 to 175 mg per tablet.
• the compressed tablets are uncoated, they may, if desired, be coated with any suitable coating agent well known in the art.
• the coating agents are those used for immediate release purposes and will dissolve in the gastric juices.
• Such coating agents are well known to those skilled in the art and include, but are not limited to hydroxypropyl methylcellulose, or methyl cellulose, or 20% w/w Opadry II, orange in water.
• the high viscosity methylcellulose such as Methocel A4M
• a binder such as povidone
• a wetting agent such as sodium lauryl sulfate
• a suitable colouring agent such as sodium lauryl sulfate
• these granular components are then admixed with additional wetting agents, and disintegrating agents and finally blended with lubricant. This final granular mixture is then blended and compressed into the tablets of the present invention.
• an aspect of the present invention is a process for preparing a tablet formulation which comprises
• step (b) adding to the mixture of step (a) a PVP aqueous solution, or alternatively spraying the mixture of step (a) with a PVP aqueous solution; and preparing granulates; and
• step (b) compacting the granulates of step (b) with the extragranular mixture of step (c).
• Another aspect of the present invention is a process for the manufacture of a pharmaceutical tablet, which process comprises mixing
• a) granulates comprising high viscosity methylcellulose of >3000 cps, a wetting agent, povidone or sodium starch glycolate, an edible calcium salt;
• step (b) compacting the granulates of step (b) with the granular mixture of step (a);
• Another aspect of the present invention is the method of relieving constipation by increasing the water content of the stool, or by providing a lubricating effect on the stool in a mammal in need thereof, which method comprises administering to said mammal, an effective amount of a high viscosity methylcellulose compressed into a tablet with a suitable diluent.
• the specified amount of PVP was weighed and added to the weighed quantity of water and stirred till all the PVP was dissolved completely.
• the moist granules were dried in the Aeromatic Fluid bed dryer in portions till the % LOD reading approximated 1.0-3.0%.
• the temperature of the air in the fluid bed dryer was maintained at approx. 90-95° C. and the sample was found to be dry at an outlet air temperature of approx. 32-52° C.
• the dried granules were milled through a 12# screen in the Fitz Mill at a high speed.
• the moisture content was measured for the dry granules.
• a sample from the granules was withdrawn and analyzed for particle size distribution, bulk and tap density, flow index, and moisture studies. The granules were weighed and ingredients of Phase B were calculated based on the weight of remaining granules.
• Target hardness desired is between 10 and 25, preferably 8-12 SCU, a preferred target weight of each tablet of less than 750 mg; an estimated friability of less than 2.0%, more preferably less than 1.0%, and target disintegration times below 30 minutes in water and acid (shorter disintegration times, less than 10 minutes, more preferably less than 8 minutes, in 0.1N HCl and less than 15 minutes in water, more preferably about 8 minutes, are preferred).
• the tablets were packaged in Ziplock bags. The tablets were tested for weight variation, hardness, disintegration in acid and water, friability, moisture (% LOD), thickness, viscosity, and content uniformity.
• the formulation in TABLE I exhibited a disintegration time of less than 5 minutes in 0.1N HCl and less than 9 minutes in water by the conventional USP method using Disintegration Apparatus with disks.
• Examples 2 to 6, and 11 to 15 are Avicel based formulations
• Examples 7 to 10 are strach based formulations which do not contain an edible calcium salt excipients. These are merely for illustration purposes, and may be formulated to include the edible calcium salts as desired using the teachings of this invention and working examples 1, and 16 to 23.
• Example 4 In an alternative embodiment of Example 4 a coated version of the formulation shown in TABLE IV was tested for disintegration time.
• the coating solution used was 20% w/w Opadry II, Orange in water.
• the average disintegration time of coated tablets was less than one minute in 0.1N HCl at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• the disintegration times using the conventional apparatus were about 1 minute in acid and less than 2 minutes in water.
• a formulation containing corn starch intragranularly, extragranular Starch 1500 and intragranular Explotab® as shown in TABLE VIII exhibited an average disintegration time of less than 14 minutes in 0.1N HCl at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• a formulation containing corn starch intragranulary, extragranular Starch 1500 and intra as well as extragranular Explotab® (in higher amounts than shown above in Example 9, TABLE IX) as shown in TABLE X exhibited an average disintegration time of less than 11 minutes in 0.1N HCl and less than 18 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• the formulation in TABLE XII exhibited an average disintegration time of less than 5 minutes in 0.1N HCl and less than 7 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• the conventional disintegration apparatus yielded less than 5 minutes in acid and less than 8 minutes in water.
• the formulation in TABLE XIII exhibited an average disintegration time of less than 10 minutes in 0.1N HCl and less than 14 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• the conventional disintegration apparatus yielded less than 14 minutes in acid and less than 22 minutes in water.
• the formulation in TABLE XIV exhibited an average disintegration time of less than 7 minutes in 0.1N HCl and less than 9 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• the conventional disintegration apparatus yielded less than 8 minutes in acid and less than 13 minutes in water.
• the formulation in TABLE XV exhibited an average disintegration time of less than 4 minutes in 0.1N HCl and less than 7 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• the conventional disintegration apparatus yielded less than 5 minutes in acid and less than 9 minutes in water.
• a formulation containing a calcium source from the intragranular and extragranular excipient, dibasic calcium phosphate, dihydrate with extragranular Explotab® is shown in TABLE XVI.
• the formulation in TABLE XVI exhibited an average disintegration time of less than 6 minutes in 0.1N HCl and less than 9 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• the conventional disintegration apparatus yielded less than 5 minutes in acid and less than 12 minutes in water.
• the formulation in TABLE XVII exhibited an average disintegration time of less than 9 minutes in 0.1N HCl and less than 14 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• the conventional disintegration apparatus yielded less than 6 minutes in acid and less than 12 minutes in water.
• Formulations containing a calcium source from the intra and extragranular excipient, dibasic calcium phosphate, dihydrate with different levels of extragranular Explotab®, in combination with similar amount of intragranular Explotab®, are shown below in TABLE XVIII and XIX (Example 19).
• the formulation in TABLE XVIII exhibited an average disintegration time of less than 6 minutes in 0.1N HCl and less than 11 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• TABLE XIX exhibited an average disintegration time of less than 9 minutes in 0.1N HCl and less than 14 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• Formulations containing a calcium source from the intra and extragranular excipient, dibasic calcium phosphate, dihydrate with extragranular Explotab® are shown in TABLE XX and XXI (Example 21) below.
• TABLE XX exhibited an average disintegration time of less than 5 minutes in 0.1N HCl and less than 13 minutes in water at 37 ⁇ 0.5° C. using the automated disintegration apparatus.
• the formulation in TABLE XXI exhibited an average disintegration time of less than 7 minutes in 0.1N HCl and less than 9 minutes in water at 37 ⁇ 0.5° C. using the conventional disintegration method.
• a formulation containing a calcium source from the intra and extragranular excipient, calcium phosphate, anhydrous with extragranular Explotab® is indicated in TABLE XXII.
• TABLE XXII exhibited an average disintegration time of less than 11 minutes in 0.1N HCl and less than 19 minutes in water at 37 ⁇ 0.5° C. using the conventional disintegration apparatus.
• a formulation containing a calcium source from the intra and extragranular excipient, tribasic calcium phosphate WG® with extragranular Explotab® is indicated in TABLE XXIII.
• the formulation in TABLE XXIII exhibited an average disintegration time of less than 13 minutes in 0.1N HCl and less than 24 minutes in water at 37 ⁇ 0.5° C. using the conventional disintegration apparatus.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Zoology (AREA)
• Inorganic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Medicinal Preparation (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)

Priority Applications (9)

Applications Claiming Priority (4)

Related Parent Applications (1)

Related Child Applications (2)

Publications (1)

Family

ID=26735831

Family Applications (9)

Family Applications After (8)

Country Status (16)

Cited By (15)

Families Citing this family (20)

Citations (1)

Family Cites Families (57)

• 1998
  • 1998-08-18 AR ARP980104076A patent/AR017512A1/es unknown
  • 1998-08-19 CO CO98047418A patent/CO4960651A1/es unknown
  • 1998-08-20 MY MYPI98003811A patent/MY128046A/en unknown
  • 1998-08-20 MY MYPI20034998A patent/MY135183A/en unknown
  • 1998-08-21 EP EP98944489A patent/EP1005329A4/en active Pending
  • 1998-08-21 BR BR9811980-0A patent/BR9811980A/pt not_active Application Discontinuation
  • 1998-08-21 NZ NZ502891A patent/NZ502891A/en unknown
  • 1998-08-21 EA EA200000246A patent/EA004803B1/ru not_active IP Right Cessation
  • 1998-08-21 AU AU92022/98A patent/AU741326B2/en not_active Ceased
  • 1998-08-21 CN CN988102943A patent/CN1215833C/zh not_active Expired - Fee Related
  • 1998-08-21 US US09/485,627 patent/US6350469B1/en not_active Expired - Lifetime
  • 1998-08-21 CN CN2004100115143A patent/CN1660054A/zh active Pending
  • 1998-08-21 KR KR1020007001825A patent/KR100743767B1/ko not_active Expired - Fee Related
  • 1998-08-21 KR KR1020077007455A patent/KR20070040424A/ko not_active Ceased
  • 1998-08-21 TW TW087113834A patent/TWI222869B/zh not_active IP Right Cessation
  • 1998-08-21 JP JP2000507349A patent/JP2001513545A/ja active Pending
  • 1998-08-21 WO PCT/US1998/017405 patent/WO1999009958A1/en not_active Ceased
  • 1998-08-21 CA CA002301135A patent/CA2301135C/en not_active Expired - Fee Related
  • 1998-08-21 KR KR1020077027417A patent/KR20070116291A/ko not_active Ceased
  • 1998-08-21 PL PL98338858A patent/PL338858A1/xx unknown
• 2001
  • 2001-12-19 US US10/024,807 patent/US20020086052A1/en not_active Abandoned
• 2003
  • 2003-06-19 US US10/464,968 patent/US20030215505A1/en not_active Abandoned
• 2004
  • 2004-11-19 US US10/993,984 patent/US20050089565A1/en not_active Abandoned
  • 2004-11-19 US US10/993,983 patent/US20050089564A1/en not_active Abandoned
  • 2004-11-19 US US10/993,458 patent/US20050089561A1/en not_active Abandoned
  • 2004-11-19 US US10/993,272 patent/US20050089560A1/en not_active Abandoned
  • 2004-11-19 US US10/993,547 patent/US7125562B2/en not_active Expired - Lifetime
  • 2004-11-19 US US10/993,550 patent/US20050089563A1/en not_active Abandoned

Patent Citations (1)

Also Published As

Similar Documents

Legal Events